Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma

Atherosclerosis

Volumn 145, Issue 2, 1999, Pages 405-413

  Inazu, Akihiro ^a   Koizumi, Junji ^b   Kajinami, Kouji ^a   Kiyohar, Tsuyoshi ^a,c   Chichibu, Kenji ^c   Mabuchi, Hiroshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^c CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Cholesteryl ester transfer protein; High density lipoprotein; Pravastatin; Probucol; Regression; Xanthoma

Indexed keywords

APOLIPOPROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; PROBUCOL; TRIACYLGLYCEROL;

ACHILLES TENDON; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; XANTHOMA;

ACHILLES TENDON; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MUSCULAR DISEASES; PRAVASTATIN; PROBUCOL; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TRIGLYCERIDES; XANTHOMATOSIS;

EID: 0032768093     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00088-X     Document Type: Article

References (56)

1. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995;36:211-8.
2. Tall AR. Plasma lipid transfer proteins. Ann Rev Biochem 1995;64:235-57.
3. Lagrost L. Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies. Biochim Biophys Acta 1994;1215:209-36.
4. Francone OL, Royer L, Haghpassand M. Increased pre-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes. J Lipid Res 1996;37:1268-77.
5. Yamamoto A, Matsuzawa Y, Yokoyama S, Funahashi T, Yamamura T, Kishino B. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol 1986;57:29H-35H.
6. Illingworth DR, Cope R, Bacon SP. Regression of tendon xanthomas in patients with familial hypercholesterolemia treated with lovastatin. South Med J 1990;83:1053-7.
7. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ. For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
8. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E. For the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
9. Johansson J, Olsson AG, Bergstrand L, Elinder LS, Nilsson S, Erikson U, Molgaard J, Holme I, Walldius G. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report. Arterioscler Thromb Vasc Biol 1995;15:1049-56.
10. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
11. Mabuchi H, Ito S, Haba T, Ueda K, Ueda R, Tatami R, Kametani T, Koizumi J, Ohta M, Miyamoto S, Takeda R, Takegoshi T. Discrimination of familial hypercholesterolemia and secondary hypercholesterolemia by Achilles' tendon thickness. Atherosclerosis 1977;28:61-8.
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
13. Kiyohara T, Kiriyama R, Zamma S, Inazu A, Koizumi J, Mabuchi H, Chichibu K. Enzyme immunoassay for cholesteryl ester transfer protein in human serum. Clin Chim Acta 1998;271:109-18.
14. Naruszewics M, Carew TE, Pittman RC, Witztum JL, Steinberg D. A novel mechanism by which probucol lowers low density lipoprotein levels demonstrated in the LDL receptor-deficient rabbit. J Lipid Res 1984;25:1206-13.
15. Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 1986;77:641-4.
16. Regnstrom J, Walldius G, Nilsson S, Elinder LS, Johansson J, Molgaard J, Holme I, Olsson AG, Nilsson J. The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. Atherosclerosis 1996;125:217-29.
17. Tsujita M, Yokoyama S. Selective inhibition of free apolipoprotein-mediated cellular lipid efflux by probucol. Biochemsitry 1996;35:13011-20.
18. Strandberg T, Kuusi T, Tilvis R, Miettinen TA. Effect of probucol on cholesterol synthesis, plasma lipoproteins and the activities of lipoprotein and hepatic lipases in the rat. Atherosclerosis 1981;40:193-201.
19. Ying H, Saku K, Harada R, Takami N, Sasaki N, Saito Y, Arakawa K. Putative mechanisms of action of probucol on high-density lipoprotein apolipoprotein A-I and its isoprotein kinetics in rabbits. Biochim Biophys Acta 1990;1047:247-54.
20. Hayek T, Chajek-Shaul T, Walsh A, Azrolan N, Breslow JL. Probucol decreases apolipoprotein A-I transport rate and increases high density lipoprotein cholesteryl ester fractional catabolic rate in control and human apolipoprotein A-I transgenic mice. Arterioscler Thromb 1991;11:1295-302.
21. McPherson R, Hogue M, Milne RW, Tall AR, Marcel YL. Increase in plasma cholesteryl ester transfer protein during probucol treatment. Relation to changes in high density lipoprotein composition. Arterioscler Thromb 1991;11:476-81.
22. Franceschini G, Chiesa G, Sirtori CR. Probucol increases cholesteryl ester transfer protein activity in hypercholesterolaemic patients. Eur J Clin Invest 1991;21:384-8.
23. Wetterau JR, Combs KA, Albers HW, Lamkin G, Stein EA, Barnhart RL, Chi EM, Jackson RL, Harmony JAK. Effects of probucol on plasma lipids, lipoproteins and parameters of high density lipoprotein metabolism. Horm Metab Res 1992;24:289-96.
24. Bagdade JD, Kaufman D, Ritter MC, Subbaiah PV. Probucol treatment in hypercholesterolemic patients: effects on lipoprotein composition, HDL particle size, and cholesteryl ester transfer. Atherosclerosis 1990;84:145-54.
25. Matsuzawa Y, Yamashita S, Funahashi T, Yamamoto A, Tarui S. Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyper-HDL2cholesterolemia with abnormal cholesteryl ester transfer. Am J Cardiol 1988;62:66B-72B.
26. Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Rezzonico L, Chiesa G, Sirtori CR. Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis 1989;9:462-9.
27. Homma Y, Ozawa H, Kobayashi T, Yamaguchi H, Sakane H, Nakamura H. Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia. Atherosclerosis 1995;114:223-34.
28. Hibino T, Sakuma N, Sato T, Yoneyama A, Fujinami T. Decrease in plasma cholesteryl-ester transfer protein activity with simvastatin treatment in patients with type IIa hypercholesterolemia. Curr Ther Res 1996;57:42-7.
29. Ahnadi C-E, Berthezene F, Ponsin G. Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. Atherosclerosis 1993;99:219-28.
30. Guerin M, Dolphin PJ, Talussot C, Gardett J, Berthezene F, Chapman MJ. Pravastatin modulates cholesteryl ester transfer from HDL to apo B-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:1359-68.
31. Cheung MC, Austin MA, Moulin P, Wolf AC, Cryer D, Knopp RH. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis 1993;102:107-19.
32. Napoli C, Leccese M, Polumbo G, de Nigris F, Chiariello P, Zuliani P, Somma P, DiLoreto M, Matteis CD, Cacciatore F, Abete P, Liguori A, Chiariello M, D'Armiento FP. Effects of vitamin E and HMG-CoA reductase inhibition on cholesteryl ester transfer protein and lecithin-cholesterol acyltransferase in hypercholesterolemia. Coron Artery Dis 1998;9:257-64.
33. Bagdade JD, Lane JT, Stone N, Ritter MC, Subbaiah PV. Persistent abnormalities in lipoprotein composition and cholesteryl ester transfer following lovastatin treatment. J Lipid Res 1990;31:1263-9.
34. Bhatnagar D, Durrington PN, Kumar S, Mackness MI, Dean J, Boulton AJM. Effect of treatment with a hydroxymethyl glutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes 1995;44:460-5.
35. Oliveira HCF, Chouinard RA, Agellon LB, Bruce C, Ma L, Walsh A, Breslow JL, Tall AR. Human cholesteryl ester transfer protein gene proximal promoter contains dietary cholesterol positive responsive elements and mediates expression in small intestine and periphery while predominant liver and spleen expression is controlled by 5′-distal sequences. J Biol Chem 1996;271:31831-8.
36. Radeau T, Lau P, Robb M, McDonnell M, Ailhaud G, McPherson R. Cholesteryl ester transfer protein (CETP) mRNA abundance in human adipose tissue: relationship to cell size and membrane cholesterol content. J Lipid Res 1995;36:2552-61.
37. Osborne TF, Rosenfeld JM. Related membrane domains in proteins of sterol sensing and cell signaling provide a glimpse of treasures still buried within the dynamic realm of intracellular metabolic regulation. Curr Opin Lipidol 1998;9:137-40.
38. Inazu A, Koizumi J, Mabuchi H, Kajinami K, Takeda R. Enhanced cholesteryl ester transfer protein activities and abnormalities of high density lipoproteins in familial hypercholesterolemia. Horm Metab Res 1992;24:284-8.
39. Carrilho AJ, Medina WL, Nakandakare ER, Quintao EC. Plasma cholesteryl ester transfer protein is lowered by treatment of hypercholesterolemia with cholestyramine. Clin Pharmacol Ther 1997;62:82-8.
40. McNamara DJ, Davidson NO, Fernandez S. In vitro cholesterol synthesis in freshly isolated mononuclear cells of human blood: effect of in vivo administration of clofibrate and/or cholestyramine. J Lipid Res 1980;21:65-71.
41. McPherson R, Agnani G, Lau P, Fruchart J-C, Edgar AD, Marcel YL. Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer. Arterioscler Thromb Vasc Biol 1996;16:1340-6.
42. McNamara DJ, Bloch CA, Botha A, Mendelsohn D. Sterol synthesis in vitro in freshly isolated blood mononuclear leukocytes from familial hypercholesterolemic patients treated with probucol. Biochim Biophys Acta 1985;833:412-6.
43. Quinet EM, Huerta P, Nancoo D, Tall AR, Marcel YL, McPherson R. Adipose tissue cholesteryl ester transfer protein mRNA in response to probucol treatment: cholesterol and species dependence. J Lipid Res 1993;34:845-52.
44. Fujita M, Shirai K. A comparative study of the therapeutic effect of probucol and pravastatin on xanthelasma. J Dermatol 1996;23:598-602.
45. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclass in the monitored atherosclerosis regression study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996;16:697-704.
46. Pfeuffer MA, Richard BM, Pittman RC. Probucol increases the selective uptake of HDL cholesteryl esters by Hep G2 human hepatoma cells. Arterioscler Thromb 1992;12:870-8.
47. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990;323:1234-8.
48. Koizumi J, Inazu A, Yagi K, Koizumi I, Uno Y, Kajinami K, Miyamoto S, Moulin P, Tall AR, Mabuchi H, Takeda R. Serum lipoprotein lipid concentration and composition in homozygous and heterozygous patients with cholesteryl ester transfer protein deficiency. Atherosclerosis 1991;90:189-96.
49. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996;97:2917-23.
50. Hirano K, Yamashita S, Nakajima N, Arai T, Maruyama T, Yoshida Y, Ishigami M, Sakai N, Kameda-Takemura K, Matsuzawa Y. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 1997;17:1053-9.
51. Chiba H, Akita H, Kotani K, Kanno T, Manabe M. Complete cholesteryl ester transfer protein deficiency increases oxidized-LDL in plasma. Rinsho. Byori., 1997;45:55-57 (in Japanese)
52. Oliveira HCF, Ma L, Milne R, Marcovina SM, Inazu A, Mabuchi H, Tall AR. Cholesteryl ester transfer protein (CETP) activity enhances plasma cholesteryl ester formation: studies in CETP transgenic mice and human genetic CETP deficiency. Arterioscler Thromb Vasc Biol 1997;17:1045-52.
53. Moriyama Y, Okamura T, Inazu A, Doi M, Iso H, Mouri Y, Ishikawa Y, Suzuki H, Iida M, Koizumi J, Mabuchi H, Komachi Y. A low prevalence of coronary heart disease in subjects with increased high-density lipoprotein cholesterol levels including those with plasma cholesteryl ester transfer protein deficiency. Prev Med 1998;27:659-67.
54. Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H, Kamada M, Mizushima A. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 1998;273:5033-6.
55. Fumeron F, Betoulle D, Luc G, Behague I, Ricard S, Poirier O, Jemaa R, Evans A, Arveiler D, Marques-Vidal P, Bard J-M, Fruchart J-C, Ducimetiere P, Apfelbaum M, Cambien F. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J Clin Invest 1995;96:1664-71.
56. Kuivenhoven JA, Jukema JW, Zwinderman AH, De Knijff P, McPherson R, Bruschke AVG, Lie KI, Kastelein JJP. For the Regression Growth Evaluation Statin Study Group. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 1998;338:86-93.